145 related articles for article (PubMed ID: 33235145)
21. A retrospective study to assess the utility of frequent laboratory monitoring of pediatric patients with sickle cell disease on hydroxyurea.
Nevin J; Myers L; Osunkwo I; Kanter J
J Pediatr Hematol Oncol; 2014 Apr; 36(3):e180-4. PubMed ID: 24072249
[TBL] [Abstract][Full Text] [Related]
22. Hydroxyurea use among children with sickle cell anemia.
Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
Pediatr Blood Cancer; 2019 Jun; 66(6):e27721. PubMed ID: 30900800
[TBL] [Abstract][Full Text] [Related]
23. Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy.
Narang I; Kadmon G; Lai D; Dhanju S; Kirby-Allen M; Odame I; Amin R; Lu Z; Al-Saleh S
Ann Am Thorac Soc; 2015 Jul; 12(7):1044-9. PubMed ID: 25970812
[TBL] [Abstract][Full Text] [Related]
24. Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use.
Crego N; Douglas C; Bonnabeau E; Earls M; Eason K; Merwin E; Rains G; Tanabe P; Shah N
J Am Board Fam Med; 2020; 33(1):91-105. PubMed ID: 31907250
[TBL] [Abstract][Full Text] [Related]
25. Adherence to hydroxyurea therapy in children with sickle cell anemia.
Thornburg CD; Calatroni A; Telen M; Kemper AR
J Pediatr; 2010 Mar; 156(3):415-9. PubMed ID: 19880135
[TBL] [Abstract][Full Text] [Related]
26. Hydroxyurea therapy in sickle cell anemia patients aids to maintain oral fungal colonization balance.
Salvia AC; Figueiredo MS; Braga JA; Pereira DF; Brighenti FL; Koga-Ito CY
J Oral Pathol Med; 2013 Aug; 42(7):570-5. PubMed ID: 23278631
[TBL] [Abstract][Full Text] [Related]
27. HABIT, a Randomized Feasibility Trial to Increase Hydroxyurea Adherence, Suggests Improved Health-Related Quality of Life in Youths with Sickle Cell Disease.
Smaldone A; Findley S; Manwani D; Jia H; Green NS
J Pediatr; 2018 Jun; 197():177-185.e2. PubMed ID: 29571930
[TBL] [Abstract][Full Text] [Related]
28. Higher oxygen saturation with hydroxyurea in paediatric sickle cell disease.
van Geyzel L; Arigliani M; Inusa B; Singh B; Kozlowska W; Chakravorty S; Bossley CJ; Ruiz G; Rees D; Gupta A
Arch Dis Child; 2020 Jun; 105(6):575-579. PubMed ID: 31871045
[TBL] [Abstract][Full Text] [Related]
29. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
Adeyemo TA; Diaku-Akinwunmi IN; Ojewunmi OO; Bolarinwa AB; Adekile AD
Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098
[TBL] [Abstract][Full Text] [Related]
30. Study protocol for ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness): Using small business partnerships to deliver a scalable and novel hydroxyurea adherence solution to youth with sickle cell disease.
Walden J; Brown L; Seiguer S; Munshaw K; Rausch J; Badawy S; McGann P; Winkler S; Gonzalez L; Creary S
PLoS One; 2024; 19(6):e0304644. PubMed ID: 38917111
[TBL] [Abstract][Full Text] [Related]
31. Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision.
Creary S; Zickmund S; Ross D; Krishnamurti L; Bogen DL
BMC Res Notes; 2015 Aug; 8():372. PubMed ID: 26303306
[TBL] [Abstract][Full Text] [Related]
32. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
[TBL] [Abstract][Full Text] [Related]
33. Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment (HABIT) efficacy trial: Community health worker support may increase hydroxyurea adherence of youth with sickle cell disease.
Green NS; Manwani D; Aygun B; Appiah-Kubi A; Smith-Whitley K; Castillo Y; Soriano L; Jia H; Smaldone AM
Pediatr Blood Cancer; 2024 Apr; 71(4):e30878. PubMed ID: 38321562
[TBL] [Abstract][Full Text] [Related]
34. Treatment adherence in patients with sickle cell anemia.
Drotar D
J Pediatr; 2010 Mar; 156(3):350-1. PubMed ID: 20056235
[No Abstract] [Full Text] [Related]
35. Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers.
Korubo KI; Onodingene NM; Okoye HC; Omunakwe HE
Ann Afr Med; 2021; 20(2):127-131. PubMed ID: 34213480
[TBL] [Abstract][Full Text] [Related]
36. Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea.
Tripathi A; Jerrell JM; Stallworth JR
Pediatr Blood Cancer; 2011 Jan; 56(1):90-4. PubMed ID: 20922765
[TBL] [Abstract][Full Text] [Related]
37. Transcranial Doppler screening in Nigerian children with sickle cell disease: A 10-year longitudinal study on the SPPIBA cohort.
Lagunju IA; Labaeka A; Ibeh JN; Orimadegun AE; Brown BJ; Sodeinde OO
Pediatr Blood Cancer; 2021 Apr; 68(4):e28906. PubMed ID: 33522690
[TBL] [Abstract][Full Text] [Related]
38. Hydroxyurea and growth in young children with sickle cell disease.
Rana S; Houston PE; Wang WC; Iyer RV; Goldsmith J; Casella JF; Reed CK; Rogers ZR; Waclawiw MA; Thompson B;
Pediatrics; 2014 Sep; 134(3):465-72. PubMed ID: 25157002
[TBL] [Abstract][Full Text] [Related]
39. Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease.
Brandow AM; Panepinto JA
Am J Hematol; 2011 Sep; 86(9):804-6. PubMed ID: 21815183
[TBL] [Abstract][Full Text] [Related]
40. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease.
de Montalembert M; Belloy M; Bernaudin F; Gouraud F; Capdeville R; Mardini R; Philippe N; Jais JP; Bardakdjian J; Ducrocq R; Maier-Redelsperger M; Elion J; Labie D; Girot R
J Pediatr Hematol Oncol; 1997; 19(4):313-8. PubMed ID: 9256830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
